Robeco Institutional Asset Management B.V. Acquires 8,833 Shares of Neurocrine Biosciences, Inc. $NBIX

Robeco Institutional Asset Management B.V. increased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 8.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 116,809 shares of the company’s stock after buying an additional 8,833 shares during the period. Robeco Institutional Asset Management B.V. owned about 0.11% of Neurocrine Biosciences worth $16,568,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in NBIX. Basecamp Wealth Advisors LLC increased its position in Neurocrine Biosciences by 582.9% in the 1st quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock valued at $31,000 after acquiring an additional 204 shares during the period. Cassaday & Co Wealth Management LLC acquired a new position in shares of Neurocrine Biosciences during the first quarter worth $33,000. Ascentis Independent Advisors acquired a new position in shares of Neurocrine Biosciences during the first quarter worth $40,000. SJS Investment Consulting Inc. lifted its holdings in shares of Neurocrine Biosciences by 67.2% during the first quarter. SJS Investment Consulting Inc. now owns 341 shares of the company’s stock worth $45,000 after purchasing an additional 137 shares during the period. Finally, TrinityBridge Ltd acquired a new position in shares of Neurocrine Biosciences during the second quarter worth $45,000. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences Trading Down 0.4%

NBIX opened at $142.70 on Friday. Neurocrine Biosciences, Inc. has a 1-year low of $122.14 and a 1-year high of $186.12. The company has a market cap of $14.51 billion, a P/E ratio of 19.79, a price-to-earnings-growth ratio of 0.63 and a beta of 0.40. The company has a fifty day moving average price of $147.49 and a two-hundred day moving average price of $153.80.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Friday, July 31st. The company reported $2.85 earnings per share for the quarter, beating the consensus estimate of $1.65 by $1.20. The firm had revenue of $959.00 million for the quarter, compared to analyst estimates of $891.16 million. Neurocrine Biosciences had a net margin of 20.91% and a return on equity of 22.43%. The business’s quarterly revenue was up 39.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.65 earnings per share. On average, research analysts forecast that Neurocrine Biosciences, Inc. will post 7.72 EPS for the current fiscal year.

Insider Activity

In related news, Director Leslie Norwalk sold 1,250 shares of the company’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $182.01, for a total transaction of $227,512.50. Following the transaction, the director directly owned 1,588 shares of the company’s stock, valued at approximately $289,031.88. This represents a 44.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David W. Boyer sold 826 shares of the stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $157.45, for a total value of $130,053.70. Following the completion of the transaction, the insider owned 8,722 shares in the company, valued at approximately $1,373,278.90. The trade was a 8.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 4,387 shares of company stock worth $720,855 in the last three months. Company insiders own 4.60% of the company’s stock.

Wall Street Analysts Forecast Growth

NBIX has been the subject of a number of recent research reports. Guggenheim initiated coverage on Neurocrine Biosciences in a report on Tuesday, October 6th. They issued a “buy” rating and a $207.00 price objective for the company. Zacks Research lowered Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 4th. Morgan Stanley lifted their target price on Neurocrine Biosciences from $182.00 to $183.00 and gave the stock an “equal weight” rating in a report on Friday, September 11th. Needham & Company LLC reaffirmed a “buy” rating and set a $204.00 target price on shares of Neurocrine Biosciences in a report on Friday, October 16th. Finally, UBS Group reduced their price target on Neurocrine Biosciences from $231.00 to $214.00 and set a “buy” rating on the stock in a research report on Tuesday, September 29th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, Neurocrine Biosciences has an average rating of “Moderate Buy” and a consensus target price of $201.14.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.